Researchers from the University of Pennsylvania presented preliminary data from a trial evaluating Regeneron Pharmaceutical‘s (NSDQ:REGN) injectable biologic drug therapy for reducing triglyceride levels. The team, led by Dr. Richard Dunbar, presented their work at the annual meeting of the American Heart Assn. The Phase I, placebo-controlled, double-blind study tested the safety and efficacy of Evinacumab, an […]
Injectable opioid dependence treatment succeeds in clinical trial
Camarus AB (STO:CAMX) and Braeburn Pharmaceuticals said this week that a late-stage trial of its injectable opioid dependence treatment was successful. CMAX shares surged 16% at the beginning of the week following the announcement. The injectable buprenorphine therapy could be another treatment used to combat the growing opioid epidemic in the United States, which claimed the lives […]
Acoustic waves used to move fluid through nanoscale channels
Researchers from the University of California San Diego used acoustic waves to move fluids through small channels, marking the 1st time that surface acoustic waves have been used at the nanoscale. The team’s work was published this week in Advanced Functional Materials. The findings are an important step towards manufacturing small, portable devices for drug discovery […]
Clearside Biomedical launches trial for Zuprata
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in clinical trial of its suspension formulation of corticosteroid triamcinolone acetonide, Zuprata, for the treatment of diabetic macular edema. The Alpharetta, Ga.-based company’s Hulk Phase I/II trial is an open-label, multi-center study designed to evaluate the safety and efficacy Zuprata administered in the suprachoroidal space […]
Zimmer Biomet touts preliminary data for stem cell therapy
Zimmer Biomet (NYSE:ZBH) touted data today from an investigational device exemption trial evaluating the use of autologous concentrated bone marrow aspirate for the treatment of critical limb ischemia. The stem cell study is the 1st pivotal trial of its kind to complete enrollment and a 1-year follow-up in a patient population that is ineligible for revascularization, […]
China’s Uni-Bio Science, Luqa Pharmaceuticals ink deal for dermatology drug-device combos
Uni-Bio Science (HKG:0690) said today that it inked a strategic partnership with Luqa Pharmaceuticals for the marketing of dermatology drug-device combination products. According to the agreement, the China-based companies can co-promote drugs or medical devices for the treatment of dermatological disorders, including existing products. The 3-year promotion agreement, with an option to renew for 2 more years, enables […]
Light-driven motor powers nanorobot drug delivery system
Researchers proposed a nanosized, light-driven motor that is powerful enough to carry a certain load and possible act as a drug delivery system, according to the study published in the Journal of Chemical Physics. “The unprecedented characteristics of dipole photomotors based on semiconductor nanoclusters offer the prospect of more than just addressing a certain scarcity of […]
Touch Surgery, Pacira to develop knee surgery sim
Touch Surgery and Pacira Pharmaceuticals (NSDQ:PCRX) launched the Exparel knee training simulation for the Touch Surgery app, designed to provide clinicians with a virtual training experience for administering the bupivacaine liposome injectable suspension in total knee arthroplasty. The simulation includes a 3D environment where clinical decisions and viewpoints are all dictated by the user and simulates […]
Seals key in new Ypsomed insulin pump
Swiss medtech company Ypsomed (SWX:YPSN) launched a portable, light-weight insulin pump with seals designed by Freudenberg Sealing Technologies. The pump, mylife YpsoPump, was introduced into the European market today. Insulin pumps, which continually transport insulin into patients, must have a very precise dosing mechanism. To facilitate a reliable measurement within the pump, there must be as […]
OCUL’s Dextenza meets endpoints in pivotal study
Ocular Therapeutix (NSDQ:OCUL) said today that its post-surgical ocular pain reliever, Dextenza, met both primary endpoints in a pivotal trial for the treatment of post-surgical ocular inflammation and pain. The product is a bioresorbable intracanalicular insert, designed for drug release to the ocular surface for up to 30 days. The randomized, double-masked study enrolled 438 patients who were […]